Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer

doi:10.3748/wjg.122397

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 33, Issue 2

This Article

(2)

(0)

(90)

Peer-Review Report of This Article

Supplementary Materials of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jan 14, 2027; 33(2): 122397
Published online Jan 14, 2027. doi: 10.3748/wjg.122397

Full Size Figure Download Figure

Figure 1 Flow diagram of the patient in the study. LAGC: Locally advanced gastric cancer; PD-1: Programmed cell death protein-1; PAC: Programmed cell death protein-1 inhibitors plus apatinib and chemotherapy; PC: Preoperative chemotherapy.

Citation: Cheng ZW, Wei M, Zhang Y, Liang YZ, Cao WB, Zhao RD, Yan ZB, Sun GR, Cui XH, Yu WB. Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer. World J Gastroenterol 2027; 33(2): 122397
URL: https://www.wjgnet.com/1007-9327/full/v33/i2/122397.htm
DOI: https://dx.doi.org/10.3748/wjg.122397

Cheng ZW, Wei M, Zhang Y, Liang YZ, Cao WB, Zhao RD, Yan ZB, Sun GR, Cui XH, Yu WB. Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer. World J Gastroenterol 2027; 33(2): 122397 [DOI: 10.3748/wjg.122397]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.